➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
Baxter
AstraZeneca
McKesson
Harvard Business School
McKinsey

Last Updated: January 24, 2021

DrugPatentWatch Database Preview

Litigation Details for Bristol-Myers Squibb Company v. Aurobindo Pharma USA Inc. (D. Del. 2017)

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Small Molecule Drugs cited in Bristol-Myers Squibb Company v. Aurobindo Pharma USA Inc.
The small molecule drugs covered by the patents cited in this case are   Start Trial and   Start Trial .

Details for Bristol-Myers Squibb Company v. Aurobindo Pharma USA Inc. (D. Del. 2017)

Date Filed Document No. Description Snippet Link To Document
2019-06-20 536 Motion to Strike MacMillan relating to infringement of U.S. Patent No. 6,967,208, Claim 104 - filed by Sigmapharm Laboratories… 5 April 2017 1:17-cv-00374 830 Patent None District Court, D. Delaware External link to document
2019-06-20 537 Letter MacMillan relating to infringement of U.S. Patent No. 6,967,208, Claim 104. (Attachments: # 1 Exhibit 1-… 5 April 2017 1:17-cv-00374 830 Patent None District Court, D. Delaware External link to document
2019-07-01 545 Letter MacMillan relating to infringement of U.S. Patent No. 6,967,208, Claim 104. (Attachments: # 1 Exhibit A,… 5 April 2017 1:17-cv-00374 830 Patent None District Court, D. Delaware External link to document
2019-12-19 684 POST Trial Brief Description ’208 Patent U.S. Patent No. 6,967,208 (JTX-1) ’945 Patent U.S. Patent No. 9,326,945…and Drug Administration Patents-in-Suit The ’208 Patent and ’945 Patent BMS Bristol-Myers…Claims For the ’208 Patent, claims 13 and 104. For the ’945 Patent, claims 21 and 22.…challenged the patents protecting Plaintiffs’ novel, blockbuster anticoagulant, Eliquis®. U.S. Patent No. 6,967,208… Eliquis®, and U.S. Patent No. 9,326,945 (the “’945 Patent”) covers certain compositions containing apixaban External link to document
2019-12-19 685 Proposed Findings of Fact Description ’208 Patent U.S. Patent No. 6,967,208 (JTX-1) ’945 Patent U.S. Patent No. 9,326,945… These consolidated cases concern U.S. Patent Nos. 6,967,208 and 9,326,945, both of which are listed…Claims For the ’208 Patent, claims 13 and 104. For the ’945 Patent, claims 21 and 22.… 4. BMS owns the ’208 Patent. UF ¶ 13. The ’208 Patent’s priority date is no later than …BMS and Pfizer jointly own the ’945 Patent. UF ¶ 26. The ’945 Patent’s priority date is no later than External link to document
2019-12-19 686 POST Trial Brief Description ’208 Patent U.S. Patent No. 6,967,208 (JTX-1) ’945 Patent U.S. Patent No. 9,326,945…challenged the patents protecting Plaintiffs’ novel, blockbuster anticoagulant, Eliquis®. U.S. Patent No. 6,967,208… Eliquis®, and U.S. Patent No. 9,326,945 (the “’945 Patent”) covers certain compositions containing apixaban…paragraph IV certification for the ’945 Patent but not the ’208 Patent, the only asserted claims against …Statement of Facts A. ’945 Patent The ’945 Patent is titled “Apixaban Formulations” and External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Boehringer Ingelheim
Colorcon
Merck
Mallinckrodt
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.